Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12

Hiroshima Journal of Medical Sciences

Volumn 49, Issue 1, 2000, Pages 29-35

  Kasaoka, Yoshinobu ^a   Nakamoto, Takahisa ^a   Wang, Jian ^a   Usui, Tsuguru ^a   Hamada, Hirofumi ^b  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Gene therapy; IL 12; Murine renal cell carcinoma

Indexed keywords

INTERLEUKIN 12;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; MOUSE;

ANIMALS; CARCINOMA, RENAL CELL; FEMALE; GENE THERAPY; INTERLEUKIN-12; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034154848     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Berg, W.J., Bukowski, R., Thompson, J.A., Nemunaitis, J., Murphy, B., Ellerhorst, J. and Motzer, R.J. 1998. A randomized phase II trial of recombinant human interleukin-12 (IL-12) versus interferon alpha-2a (IFN) in advanced renal cell carcinoma (RCC). Proc. ASCO. 17: 318a.
2. Brunda, M.J., Luistro, L., Warrier, R.R., Wright, R.B., Hubbard, B.R., Murphy, M., Wolf, S.F. and Gately, M.K. 1993. Antitumor and antimetastatic activity of Interleukine12 against murine tumors. J. Exp. Med. 178: 1223-1230.
3. Bramson, J.L., Hitt, M., Addison, C.L., Muller, W.J., Gauldie, J. and Graham, F.L. 1996. Direct intratumoral injection of an adenovirus expressing interlukin-12 induces regression and long-lasting immunity: That is associated with highly localized expression of Interleukin-12. Hum. Gene Ther. 7: 1995-2002.
4. Coen, J. 1995. IL-12 deaths: explanation and puzzle. Science 270: 908.
5. Dranoff, G., Jaffee, E., Lazenby A., Golumbek, P., Levisky H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90: 3539-3543.
6. Gately, M.K., Warrier, R.R., Honasoge, S., Carvajal, D.M., Sarmiento, U., Hubbard, B.R. and Murphy, M. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocytes activity and induces production of IFN-γ in vivo. Int. Immunol. 6: 157-167.
7. Gubler, U., Chua, A.O., Schoenhaut, D.S., Dwyer, C.M., McComa, W., Motyka, R., Nabavi, N., Wolitzky, A.G., Quinn, P.M., Familletti, P.C. and Gately, M.K. 1991. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA. 88: 4143-4147.
8. Jaffe, E.M., Dranoff, G., Cohen, L.K., Hauda, M.K., Clift, S., Marshall, F.F., Mulligan, R.C. and Pardell, D.M. 1993. High efficacy gene transfer into primary human tumor explants without cell selection. Cancer Res. 53: 2221-2226.
9. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R.M., Clark, S.C., Chang, S., Loudon, R., Scherman, F., Perussia, B. and Trinchieri, G. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845.
10. Motzer, R.J., Rakhit, A., Schwartz, L.H., Olencki, T., Malone, T.M., Sandstrom, K., Nadeau, R., Parmar, H. and Bukowski, R. 1998. Phase I trial of subcutaneous recombinant human Interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Res. 4: 1183-1191.
11. Mulders, P., Figlin, R., deKernion, B.J., Wiltrout, R., Linehan, M., Parkinson, D., deWolf, W. and Belidegrum, A. 1997. Renal cell carcinoma: recent progress and future directions. Cancer Res. 57: 5189-5195.
12. Murphy, G.P. and Hrushesky, W.J. 1973. A murine renal cell carcinoma. J. Natl. Cancer Inst. 50: 1013-1025.
13. Nakamoto, T., Mitani, S., Usui, A., Ikemoto, H., Usui, T. and Nakano, H. 1990. Surgical treatment of renal cell carcinoma I.: Results of curative nephrectomy for renal cell carcinoma without distant metastases. Nishinihon J. Urol. 52: 701-704.
14. Nakamoto, T., Mitani, S., Usui, A., Ikemoto, H., Usui, T. and Nakano, H. 1990. Surgical treatment of renal cell carcinoma II.: Results of adjunctive nephrectomy for renal cell carcinoma with distant metastases. Nishinihon J. Urol. 52: 705-708.
15. Nastala, C.L., Edington, H., Storkus, W., Mckinney, T.G., Brunda, M., Gately, M.K., Wolf, S.F., Schreiber, R. and Lotze, M.T. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ. J. Immunol. 153: 1697-1706.
16. Robertson, M.J. and Ritz, J. 1996 Interleukin-12: Basic biology and potential application in cancer treatment. The Oncologist. 1: 93-102.
17. Sarmiento, U.M., Riley, J.H., Knaack, P.A., Lipman, J.M., Becker, J.M., Gately, M.K., Chizzonite, R. and Anderson, T.D. 1994. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest. 71: 862-873.
18. Stern, A.S., Podlaski, F.J., Hulmes, J.D., Pan, Y.C.E., Quinn, P.M., Wolitzky, A.G., Familletti, P.C., Stremlo, D.L., Truitt, T., Chizzonite, R. and Gately, M.K. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA. 87: 6808-6812.
19. Tahara, H., Zeh III, H.J., Storkus, W.J., Pap, I., Watkins, S.C., Gubler, U., Wolf, S.F., Robbins, P.D. and Lotze, M.T. 1994. Fibroblasts genetically engineered to secrete Interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182-189.
20. Tahara, H., Zitvogel, L., Storkus, W.J., Zeh III, H.J., McKinney, T.G., Schreiber, R.D., Gubler, U., Robbins, P.D. and Lotze, M.T. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154: 6466-6474.
21. Tare, N.S., Bowen, S., Warrier, R.W., Carvajal, D.M., Benjamin, W.R., Riley, J.H., Anderson, T.D. and Gately, M.K. 1995. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in bone marrow but enhances hematopoiesis in the spleen. J. Interferon Cytokine Res. 15: 377-383.
22. Voest, E.E., Kenyan, B., O'Reilly, M.S., Truitt, G., D'Amato, R.J. and Folkman, J. 1995. Inhibition of angiogenesis in vivo by Interleukin 12. J. Natl. Cancer Inst. 87: 581-586.
23. Wirth, M.P. 1993. Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am. 20: 283-295.
24. Zitvogel, L., Tahara, H., Cai, Q., Storkus, W.J., Muller, G., Wolf, S.F., Gately M., Robbins, P.D. and Lotze, M.T. 1994. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther. 5: 1493-1506.